PRTC - PureTech Phase 2 study for anti-anxiety drug LYT-300 meets primary endpoint November, 14 2023 02:09 PM PureTech Health plc 2023-11-14 14:09:36 ET More on PureTech PureTech reports 1H results Seeking Alpha’s Quant Rating on PureTech Historical earnings data for PureTech Financial information for PureTech For further details see: PureTech Phase 2 study for anti-anxiety drug LYT-300 meets primary endpoint